Safety and effectiveness of percutaneous embolization for late failed renal allograft in patients with graft intolerance syndrome.

OBJECTIVE: To investigate the clinical safety and effectiveness of percutaneous embolization in treating the late failed renal allograft in patients with graft intolerance syndrome (GIS). METHODS: Transcatheter embolization of renal graft artery was performed in 18 patients with late graft dysfunction and GIS. The subsequent complications, postoperative symptom remission rate, and prognosis were assessed. RESULTS: GIS was relieved in 15 patients (83.3%), of which 6 patients (33.3%) had severer fever and pain in the area of renal graft after embolization, which lasted for a mean of 3.5 days (range: 2-5 days). GIS persisted for more than 2 weeks in 3 patients (16.7%), who ultimately underwent surgical removal of grafts. No severe embolism-associated complications were noted. CONCLUSION: Percutaneous embolization can effectively avoid surgical graft removal in patients with late renal allograft failure, and therefore can be used as a safe and effective treatment for the late failed renal allograft combined with GIS.

[Expression and clinical significance of serum VEGF and bFGF in children with acute leukemia].

AIM: To study the expression and clinical significance of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in children with acute leukemia (AL). METHODS: The serum VEGF and bFGF level before chemotherapy from 40 cases of children with newly diagnosed AL, after 1 course of treatment from from 37 cases of children with complete remission (CR) and no- remission(NR) , and 40 cases of healthy children (control group) were detected by ELISA technology. RESULTS: Before treatment, the serum VEGF and bF-GF level of the AL group and different types of AL were significantly higher than the control group(P<0.05), while the serum VEGF and bFGF level were no significant difference between the different types of AL ( P > 0.05). Before treatment, the serum VEGF and bFGF level were no significant difference between the AL CR and NR children; After treatment, the serum VEGF and bFGF level of CR children decreased significantly, compared with the prior-treatment and NR children the different was significant ( P < 0. 05); While the serum VEGF and bFGF level of NR children were no significant difference between prior-treatment and post-treatment. CONCLUSION: The serum VEGF and bFGF level have high expression in children with AL, the serum VEGF and bFGF level can be used as indicators of AL efficacy, and are correlation with the prognosis of children with AL.